<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34677601</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6613</ISSN><JournalIssue CitedMedium="Internet"><Volume>224</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of infectious diseases</Title><ISOAbbreviation>J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.</ArticleTitle><Pagination><StartPage>1839</StartPage><EndPage>1848</EndPage><MedlinePgn>1839-1848</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/infdis/jiab490</ELocationID><Abstract><AbstractText Label="BACKGROUND">The biological processes associated with postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) are unknown.</AbstractText><AbstractText Label="METHODS">We measured soluble markers of inflammation in a SARS-CoV-2 recovery cohort at early (&lt;90 days) and late (&gt;90 days) timepoints. We defined PASC as the presence of 1 or more coronavirus disease 2019 (COVID-19)-attributed symptoms beyond 90 days. We compared fold-changes in marker values between those with and without PASC using mixed-effects models with terms for PASC and early and late recovery time periods.</AbstractText><AbstractText Label="RESULTS">During early recovery, those who went on to develop PASC generally had higher levels of cytokine biomarkers including tumor necrosis factor-&#x3b1; (1.14-fold higher mean ratio [95% confidence interval {CI}, 1.01-1.28]; P&#x2005;=&#x2005;.028) and interferon-&#x3b3;-induced protein 10 (1.28-fold higher mean ratio [95% CI, 1.01-1.62]; P&#x2005;=&#x2005;.038). Among those with PASC, there was a trend toward higher interleukin 6 levels during early recovery (1.29-fold higher mean ratio [95% CI, .98-1.70]; P&#x2005;=&#x2005;.07), which became more pronounced in late recovery (1.44-fold higher mean ratio [95% CI, 1.11-1.86]; P&#x2005;&lt;&#x2005;.001). These differences were more pronounced among those with a greater number of PASC symptoms.</AbstractText><AbstractText Label="CONCLUSIONS">Persistent immune activation may be associated with ongoing symptoms following COVID-19. Further characterization of these processes might identify therapeutic targets for those experiencing PASC.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peluso</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0003-0585-6230</Identifier><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Alex F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durstenfeld</LastName><ForeName>Matthew S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Division of Cardiology, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Hsi-En</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Sarah A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forman</LastName><ForeName>Carrie A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munter</LastName><ForeName>Sadie E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoh</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tai</LastName><ForeName>Viva</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chenna</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Monogram Biosciences Inc, South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yee</LastName><ForeName>Brandon C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Monogram Biosciences Inc, South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winslow</LastName><ForeName>John W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Monogram Biosciences Inc, South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petropoulos</LastName><ForeName>Christos J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Monogram Biosciences Inc, South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenhouse</LastName><ForeName>Bryan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hunt</LastName><ForeName>Peter W</ForeName><Initials>PW</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsue</LastName><ForeName>Priscilla Y</ForeName><Initials>PY</Initials><AffiliationInfo><Affiliation>Division of Cardiology, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Jeffrey N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daniel Kelly</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glidden</LastName><ForeName>David V</ForeName><Initials>DV</Initials><Identifier Source="ORCID">0000-0001-5888-1419</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deeks</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henrich</LastName><ForeName>Timothy J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 AI145806</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AI060530</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K12 HL143961</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AI112393</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI141003</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AI144048</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>National Institute of Allergy and Infectious Diseases</Agency><Country/></Grant><Grant><GrantID>K23 AI076614</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>3R01AI141003-03S1</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Infect Dis</MedlineTA><NlmUniqueID>0413675</NlmUniqueID><ISSNLinking>0022-1899</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="Y">Inflammation</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">IL-6</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">TNF-&#x3b1;</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">coronavirus</Keyword><Keyword MajorTopicYN="N">immune activation</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">postacute sequelae of SARS-CoV-2 infection</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>22</Day><Hour>12</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34677601</ArticleId><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="doi">10.1093/infdis/jiab490</ArticleId><ArticleId IdType="pii">6376537</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lucas C, Wong P, Klein J, et al. ; Yale IMPACT Team. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 2020; 584:463&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Valle DM, Kim-Schulze S, Huang HH, et al. . An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 2020; 26:1636&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7869028</ArticleId><ArticleId IdType="pubmed">32839624</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. . Post-acute COVID-19 syndrome. Nat Med 2021; 27:601&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B, Mohn KG-I, Brokstad KA, et al. . Long COVID in a prospective cohort of home-isolated patients. Nat Med 2021; 27:1607&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature 2021; 594:259&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavillegrand JR, Garnier M, Spaeth A, et al. . Elevated plasma IL-6 and CRP levels are associated with adverse clinical outcomes and death in critically ill SARS-CoV-2 patients: inflammatory response of SARS-CoV-2 patients. Ann Intensive Care 2021; 11:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7804215</ArticleId><ArticleId IdType="pubmed">33439360</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharifpour M, Rangaraju S, Liu M, et al. ; Emory COVID-19 Quality and Clinical Research Collaborative. C-reactive protein as a prognostic indicator in hospitalized patients with COVID-19. PLoS One 2020; 15:e0242400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7679150</ArticleId><ArticleId IdType="pubmed">33216774</ArticleId></ArticleIdList></Reference><Reference><Citation>Herold T, Jurinovic V, Arnreich C, et al. . Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients. medRxiv [Preprint]. Posted online 10 April 2020. doi:10.1101/2020.04.01.20047381.</Citation></Reference><Reference><Citation>Laing AG, Lorenc A, Del Molino Del Barrio I, et al. . A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med 2020; 26:1623&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">32807934</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H, Ma Q, Li C, et al. . Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect 2020; 9:1123&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7473317</ArticleId><ArticleId IdType="pubmed">32475230</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonny TS, Patel EU, Zhu X, et al. . Cytokine and chemokine levels in coronavirus disease 2019 convalescent plasma. Open Forum Infect Dis 2021; 8:ofaa574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7717355</ArticleId><ArticleId IdType="pubmed">33553467</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong SWX, Fong S-W, Young BE, et al. . Persistent symptoms and association with inflammatory cytokine signatures in recovered coronavirus disease 2019 patients. Open Forum Infect Dis 2021; 8:ofab156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8083585</ArticleId><ArticleId IdType="pubmed">34095336</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, Wang Z, Lorenzi JCC, et al. . Evolution of antibody immunity to SARS-CoV-2. Nature 2021; 591:639&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenorio AR, Zheng Y, Bosch RJ, et al. . Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis 2014; 210:1248&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4192039</ArticleId><ArticleId IdType="pubmed">24795473</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Villar S, Sainz T, Lee SA, et al. . HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog 2014; 10:e1004078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022662</ArticleId><ArticleId IdType="pubmed">24831517</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt PW, Sinclair E, Rodriguez B, et al. . Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis 2014; 210:1228&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4192038</ArticleId><ArticleId IdType="pubmed">24755434</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Kelly JD, Lu S, et al. . Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19. medRxiv [Preprint]. Posted online 13 March 2021. doi:10.1101/2021.03.11.21252311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.11.21252311</ArticleId></ArticleIdList></Reference><Reference><Citation>
Centers for Disease Control and Prevention.
Symptoms of COVID-19. 2021. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html. Accessed 7 July 2021.</Citation></Reference><Reference><Citation>Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med 2002; 64:258&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">11914441</ArticleId></ArticleIdList></Reference><Reference><Citation>
Ayoubkhani D. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK&#x2014;Office for National Statistics. Office for National Statistics.2021. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021. Accessed 7 April 2021.</Citation></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. . Attributes and predictors of long COVID. Nat Med 2021; 27:626&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol 2018; 18:773&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">30254251</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong Y, Tracey KJ, Moldawer LL, et al. . Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med 1989; 170:1627&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2189514</ArticleId><ArticleId IdType="pubmed">2809510</ArticleId></ArticleIdList></Reference><Reference><Citation>Thwaites RS, Sanchez Sevilla Uruchurtu A, Siggins MK, et al. . Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. Sci Immunol 2021; 6:eabg9873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8128298</ArticleId><ArticleId IdType="pubmed">33692097</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Yu B, Yang Y, et al. . Immunological and inflammatory profiles during acute and convalescent phases of severe/critically ill COVID-19 patients. Int Immunopharmacol 2021; 97:107685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8052478</ArticleId><ArticleId IdType="pubmed">33951560</ArticleId></ArticleIdList></Reference><Reference><Citation>Galv&#xe1;n-Rom&#xe1;n JM, Rodr&#xed;guez-Garc&#xed;a SC, Roy-Vallejo E, et al. . IL-6 serum levels predict severity and response to tocilizumab in COVID-19: an observational study. J Allergy Clin Immunol 2021; 147:72&#x2013;80.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7525244</ArticleId><ArticleId IdType="pubmed">33010257</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group; Horby PW, Pessoa-Amorim G, et al. . Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021; 397:1637&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8084355</ArticleId><ArticleId IdType="pubmed">33933206</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon AC, Mouncey PR, Al-Beidh F, et al. ; REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med 2021; 384:1491&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7953461</ArticleId><ArticleId IdType="pubmed">33631065</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P; CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med 2021; 181:32&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7577198</ArticleId><ArticleId IdType="pubmed">33080017</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone JH, Frigault MJ, Serling-Boyd NJ, et al. ; BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med 2020; 383:2333&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7646626</ArticleId><ArticleId IdType="pubmed">33085857</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvarani C, Dolci G, Massari M, et al. ; RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med 2021; 181:24&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7577199</ArticleId><ArticleId IdType="pubmed">33080005</ArticleId></ArticleIdList></Reference><Reference><Citation>Salama C, Han J, Yau L, et al. . Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med 2021; 384:20&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7781101</ArticleId><ArticleId IdType="pubmed">33332779</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol 2015; 16:448&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">25898198</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 2001; 4:1116&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">11600888</ArticleId></ArticleIdList></Reference><Reference><Citation>Papathanasiou S, Rickelt S, Soriano ME, et al. . Tumor necrosis factor-&#x3b1; confers cardioprotection through ectopic expression of keratins K8 and K18. Nat Med 2015; 21:1076&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5419049</ArticleId><ArticleId IdType="pubmed">26280121</ArticleId></ArticleIdList></Reference><Reference><Citation>Suematsu S, Matsuda T, Aozasa K, et al. . IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A 1989; 86:7547&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC298102</ArticleId><ArticleId IdType="pubmed">2798426</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell IL, Abraham CR, Masliah E, et al. . Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci U S A 1993; 90:10061&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47713</ArticleId><ArticleId IdType="pubmed">7694279</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 2009; 104:236&#x2013;44, 28p following 244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5482545</ArticleId><ArticleId IdType="pubmed">19074475</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol 2016; 12:49&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4809675</ArticleId><ArticleId IdType="pubmed">26656660</ArticleId></ArticleIdList></Reference><Reference><Citation>Seow J, Graham C, Merrick B, et al. . Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol 2020; 5:1598&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7610833</ArticleId><ArticleId IdType="pubmed">33106674</ArticleId></ArticleIdList></Reference><Reference><Citation>Long QX, Tang XJ, Shi QL, et al. . Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 2020; 26:1200&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">32555424</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudbjartsson DF, Norddahl GL, Melsted P, et al. . Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med 2020; 383:1724&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7494247</ArticleId><ArticleId IdType="pubmed">32871063</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Zuiani A, Fischinger S, et al. . Quick COVID-19 healers sustain anti-SARS-CoV-2 antibody production. Cell 2020; 183:1496&#x2013;507.e16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7608032</ArticleId><ArticleId IdType="pubmed">33171099</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowitdamrong E, Puthanakit T, Jantarabenjakul W, et al. . Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019. PLoS One 2020; 15:e0240502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7546485</ArticleId><ArticleId IdType="pubmed">33035234</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Yuan Q, Wang H, et al. . Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin Infect Dis 2020; 71:2027&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184337</ArticleId><ArticleId IdType="pubmed">32221519</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Takahashi S, Hakim J, et al. . SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. Sci Adv. 2021; 7: eabh3409. doi:10.1126/sciadv.abh3409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abh3409</ArticleId><ArticleId IdType="pmc">PMC8324059</ArticleId><ArticleId IdType="pubmed">34330709</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang SE, Feng A, Meng W, et al. . New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun 2021; 12:5417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhadelia N, Belkina AC, Olson A, et al. . Distinct autoimmune antibody signatures between hospitalized acute COVID-19 patients, SARS-CoV-2 convalescent individuals, and unexposed pre-pandemic controls. medRxiv [Preprint]. Posted 25 January 2021. doi:10.1101/2021.01.21.21249176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.21.21249176</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubino F, Amiel SA, Zimmet P, et al. . New-onset diabetes in Covid-19. N Engl J Med 2020; 383:789&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7304415</ArticleId><ArticleId IdType="pubmed">32530585</ArticleId></ArticleIdList></Reference><Reference><Citation>Brancatella A, Ricci D, Viola N, Sgr&#xf2; D, Santini F, Latrofa F. Subacute thyroiditis after SARS-CoV-2 infection. J Clin Endocrinol Metab 2020; 105:dgaa276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7314004</ArticleId><ArticleId IdType="pubmed">32436948</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>